The medical profession is aware, they just aren’t scaled up for use in any meaningful sense - essentially to be able to meaningfully fight bacterial infections with phases a hospital or clinic would need to type the bacteria and screen it against potentially hundreds or more phages (even if they are already specific to the bacteria) to find the ones that are going to be most effective. So, there are time constraints, delivery mechanisms and also logistics to overcome.

A challenge for a startup?